Neobe Therapeutics

Executive Summary

Neobe Therapeutics is a preclinical-stage biotechnology company headquartered in Cambridge, UK, focused on developing engineered live biotherapeutics for oncology. Founded in 2019, the company leverages a proprietary synthetic biology platform to design programmable microbial therapies that remodel the tumor microenvironment. By targeting immune-excluded solid tumors, Neobe aims to overcome a key barrier to immunotherapy efficacy, potentially unlocking response rates in patient populations refractory to current checkpoint inhibitors. The platform enables precise engineering of bacterial strains to deliver therapeutic payloads, modulate immune signaling, and degrade immunosuppressive factors within the tumor, offering a differentiated approach to cancer treatment. As a private, early-stage venture, Neobe's progress to date has primarily centered on platform validation and preclinical proof-of-concept studies. The company has not disclosed total funding or valuation, but its innovative approach positions it within a growing field of microbiome-based oncology therapies. Key risks include technical challenges in bacterial engineering, regulatory hurdles for live biotherapeutics, and competition from other microbial therapy developers. Near-term value inflection points will depend on successful fundraising, IND-enabling studies, and initial clinical data. Given the early stage and limited public information, conviction in Neobe's outlook is moderate, acknowledging both the therapeutic potential and the significant execution risks inherent in synthetic biology drug development.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Financing Round70% success
• Q2 2027IND Filing for Lead Program40% success
• Q4 2027First-in-Human Study Initiation30% success